The Corporation focused on the Biology of healing has this week held its AGM. In the presentation given at the meeting, some time was devoted to ProMetic’s growing understanding of the role of Plasminogen in the body’s healing process. This potentially expands the addressable patient population exponentially beyond the 2,000 (circa 4 x more than originally anticipated) sufferers of congenital Plasminogen deficiency for whom Prometic is targeting a commercial launch in Q4 this year
12 May 2017
Beyond Congenital Plasminogen Deficiency
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Beyond Congenital Plasminogen Deficiency
ProMetic Life Sciences (PLI:TSE) | 0 0 1.3% | Mkt Cap: 1,075m
- Published:
12 May 2017 -
Author:
Derren Nathan -
Pages:
8
The Corporation focused on the Biology of healing has this week held its AGM. In the presentation given at the meeting, some time was devoted to ProMetic’s growing understanding of the role of Plasminogen in the body’s healing process. This potentially expands the addressable patient population exponentially beyond the 2,000 (circa 4 x more than originally anticipated) sufferers of congenital Plasminogen deficiency for whom Prometic is targeting a commercial launch in Q4 this year